User type: User
Registered: 2021-07-13 15:17:13
The global Non-Invasive Prenatal Testing Market is forecasted to reach USD 8.75 Billion by 2027, according to a new report by Emergen Research. Non-invasive prenatal testing (NIPT), commonly known as cell-free DNA testing, is regarded as a significant extension to the variety of diagnostic methods used to detect fetal chromosome defects. NIPT is also considered superior to other screening modalities, particularly for trisomy 21 (one of the most prevalent congenital anomalies). NIPT enables individuals to make informed decisions as to whether diagnostic testing should be carried out. Associated fetal chromosomal anomalies typically include the benefit or lack of genetic material that can differ from small segments to small segments of chromosomes to entire chromosomes.
Despite NIPT being accessible in growing amounts of regions, there is a major commercial push expected to assist consumer expansion in the projected years. NIPT was confirmed through similarities with standard prenatal aneuploidy screening and found to be a beneficial screening procedure with keen sensitivity and specificity. Increasing popularity among pregnant women as an alternative to amniocentesis and awareness of prenatal genetic problems drives non-invasive prenatal testing.
At Emergen Research, we believe in advancing with technology.
We are a growing market research and strategy consulting company with an
exhaustive knowledge base of cutting-edge and potentially market-disrupting
technologies that are predicted to become more prevalent in the coming decade.